Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models

References

• Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: Current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9:89–104. doi:10.1111/cts.12391. PMID:26924066.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. doi:10.1038/nature10673. PMID:22193102.
   PubMed Web of Science ®Google Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175–208. doi:10.1146/annurev.immunol.24.021605.090733. PMID:16551247.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. doi:10.1126/science.1129139. PMID:17008531.
   PubMed Web of Science ®Google Scholar
• Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, et al. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014;3:e963424. doi:10.4161/21624011.2014.963424. PMID:25941593.
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res. 2016;22:2155–66. doi:10.1158/1078-0432.CCR-15-2205. PMID:26712687.
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73:1063–75. doi:10.1158/0008-5472.CAN-12-2583. PMID:23345163.
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166:4254–9. doi:10.4049/jimmunol.166.6.4254. PMID:11238679.
   PubMed Web of Science ®Google Scholar
• Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JF, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15:2531–40. doi:10.1158/1078-0432.CCR-08-2729. PMID:19318472.
   PubMed Web of Science ®Google Scholar
• Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118:1165–75. PMID:18259609.
   PubMed Web of Science ®Google Scholar
• Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One. 2010;5:e11144. doi:10.1371/journal.pone.0011144. PMID:20585396.
   PubMed Web of Science ®Google Scholar
• Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol. 2012;2012:425476. doi:10.1155/2012/425476. PMID:22505809.
   PubMed Web of Science ®Google Scholar
• Ghirelli C, Hagemann T. Targeting immunosuppression for cancer therapy. J Clin Invest. 2013;123:2355–7. doi:10.1172/JCI69999. PMID:23728169.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013;123:2447–63. doi:10.1172/JCI64859. PMID:23728179.
   PubMed Web of Science ®Google Scholar
• Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22–7. doi:10.1016/j.coi.2014.12.009. PMID:25597442.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61–73. doi:10.1016/j.immuni.2013.07.005. PMID:23890064.
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Nijman HW, Daemen T. From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol. 2011;2011:439053. doi:10.1155/2011/439053. PMID:22190971.
   PubMedGoogle Scholar
• Jeanbart L, Swartz MA. Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A. 2015;112:14467–72. doi:10.1073/pnas.1508516112. PMID:26598681.
   PubMed Web of Science ®Google Scholar
• Pang IK, Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus. Nat Immunol. 2013;14:246–53. doi:10.1038/ni.2514. PMID:23314004.
   PubMed Web of Science ®Google Scholar
• Wallgren AC, Andersson B, Backer A, Karlsson-Parra A. Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: a functional link between direct and indirect allosensitization. Scand J Immunol. 2005;62:234–42. doi:10.1111/j.1365-3083.2005.01663.x. PMID:16179010.
   PubMed Web of Science ®Google Scholar
• Laurell A, Lönnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J ImmunoTher Cancer. 2017;5:52. doi:10.1186/s40425-017-0255-0. PMID:28642820.
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769–76. doi:10.1038/ni1223. PMID:15995707.
   PubMed Web of Science ®Google Scholar
• Ramachandran M, Jin C, Yu D, Eriksson F, Essand M. Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol. 2014;193:2287–96. doi:10.4049/jimmunol.1400339. PMID:25049358.
   PubMed Web of Science ®Google Scholar
• Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci U S A. 2004;101:998–1003. doi:10.1073/pnas.0306407101. PMID:14722354.
   PubMed Web of Science ®Google Scholar
• Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507:109–13. doi:10.1038/nature13111. PMID:24572365.
   PubMed Web of Science ®Google Scholar
• Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490:412–6. doi:10.1038/nature11538. PMID:23051752.
   PubMed Web of Science ®Google Scholar
• Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:608406. doi:10.1155/2012/608406. PMID:22927846.
   PubMedGoogle Scholar
• Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356–64. doi:10.1172/JCI80005. PMID:26168215.
   PubMed Web of Science ®Google Scholar
• Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014;41:947–59. doi:10.1016/j.immuni.2014.10.020. PMID:25500368.
   PubMed Web of Science ®Google Scholar
• Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771–5. doi:10.1038/nature05543. PMID:17220874.
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571–80. doi:10.1016/j.it.2014.09.006. PMID:25443495.
   PubMed Web of Science ®Google Scholar
• Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol. 2003;170:2817–23. doi:10.4049/jimmunol.170.6.2817. PMID:12626531.
   PubMed Web of Science ®Google Scholar
• Maroof A, Beattie L, Kirby A, Coles M, Kaye PM. Dendritic cells matured by inflammation induce CD86-dependent priming of naive CD8+ T cells in the absence of their cognate peptide antigen. J Immunol. 2009;183:7095–103. doi:10.4049/jimmunol.0901330. PMID:19917700.
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15:e257–67. doi:10.1016/S1470-2045(13)70585-0. PMID:24872109.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569–80. doi:10.1084/jem.20030590. PMID:12925674.
   PubMed Web of Science ®Google Scholar
• Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004;173:7209–16. doi:10.4049/jimmunol.173.12.7209. PMID:15585842.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20:1747–56. doi:10.1158/1078-0432.CCR-13-2116. PMID:24691639.
   PubMed Web of Science ®Google Scholar
• Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol. 2011;85:13114–23. doi:10.1128/JVI.05759-11. PMID:21957304.
   PubMed Web of Science ®Google Scholar
• Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B, et al. Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS One. 2013;8:e54952. doi:10.1371/journal.pone.0054952. PMID:23372800.
   PubMed Web of Science ®Google Scholar